Safety and Effectiveness of Daptomycin Across a Hospitalized Obese Population: Results of a Multicenter Investigation in the Southeastern United States

Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010

(2012) Katherine M. Flegal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Surgical Site Infections and Cost in Obese Patients Undergoing Colorectal Surgery

(2011) Elizabeth C. Wick   ARCHIVES OF SURGERY

Vancomycin: We Can't Get There From Here

(2011) N. Patel et al.   CLINICAL INFECTIOUS DISEASES

Successful re-challenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin

(2011) Christopher M. Bland et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

High-Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: A Large, Multicenter, Retrospective Study

(2011) Ravina Kullar et al.   PHARMACOTHERAPY

Availability of information for dosing injectable medications in underweight or obese patients

(2010) K. A. Jacques et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Treatment of Meningitis Caused by Vancomycin-Resistant Enterococcus faecium: High-Dose and Combination Daptomycin Therapy

(2010) Jennifer Le et al.   ANNALS OF PHARMACOTHERAPY

Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

(2010) Sujata M. Bhavnani et al.   CLINICAL INFECTIOUS DISEASES

Obesity as a Risk Factor for Nosocomial Infections in Trauma Patients

(2010) Pablo E. Serrano et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Surgical Site Infections Following Bariatric Surgery in Community Hospitals: A Weighty Concern?

(2010) Joshua T. Freeman et al.   OBESITY SURGERY

Estimation of creatinine clearance in morbidly obese patients

(2009) Jasmina A. Demirovic et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

(2009) Pamela A Moise et al.   ANNALS OF PHARMACOTHERAPY

Safety of High‐Dose Intravenous Daptomycin Treatment: Three‐Year Cumulative Experience in a Clinical Program

(2009) D. A. Figueroa et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor

(2009) R. O. Odero et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Obesity and Site-Specific Nosocomial Infection Risk in the Intensive Care Unit

(2009) Lesly A. Dossett et al.   Surgical Infections

Cost of bloodstream infections

(2008) Meredith Kilgore et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

(2008) W. E. Rose et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria

(2008) D. E. Katz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE